APA

Burris H. A., Dowlati A., Moss R. A., Infante J. R., Jones S. F., Spigel D. R., Levinson K. T., Lindquist D., Gainer S. D., Dar M. M., Suttle A. B., Ball H. A. & Tan A. R. (20121217). Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. : Molecular cancer therapeutics.

Chicago

Burris Howard A, Dowlati Afshin, Moss Rebecca A, Infante Jeffrey R, Jones Suzanne F, Spigel David R, Levinson Kelly T, Lindquist Diana, Gainer Shelby D, Dar Mohammed M, Suttle A Benjamin, Ball Howard A and Tan Antoinette R. 20121217. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. : Molecular cancer therapeutics.

Harvard

Burris H. A., Dowlati A., Moss R. A., Infante J. R., Jones S. F., Spigel D. R., Levinson K. T., Lindquist D., Gainer S. D., Dar M. M., Suttle A. B., Ball H. A. and Tan A. R. (20121217). Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. : Molecular cancer therapeutics.

MLA

Burris Howard A, Dowlati Afshin, Moss Rebecca A, Infante Jeffrey R, Jones Suzanne F, Spigel David R, Levinson Kelly T, Lindquist Diana, Gainer Shelby D, Dar Mohammed M, Suttle A Benjamin, Ball Howard A and Tan Antoinette R. Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. : Molecular cancer therapeutics. 20121217.